Intranasal Vaccination with a Lentiviral Vector Protects against SARS-CoV-2 in Preclinical Animal Models

Ku, Min-Wen; Bourgine, Maryline; Authié, Pierre; Lopez, Jodie; Nemirov, Kirill; Moncoq, Fanny; Noirat, Amandine; Vesin, Benjamin; Nevo, Fabien; Blanc, Catherine; Souque, Philippe; Tabbal, Houda; Simon, Emeline; Hardy, David; Le Dudal, Marine; Guinet, Françoise; Fiette, Laurence; Mouquet, Hugo; Anna, François; Martin, Annette; Escriou, Nicolas; Majlessi, Laleh; Charneau, Pierre

To develop a vaccine candidate against COVID-19, we generated a Lentiviral Vector (LV), eliciting neutralizing antibodies against the Spike glycoprotein of SARS-CoV-2. Systemic vaccination by this vector in mice, in which the expression of the SARS-CoV-2 receptor hACE2 has been induced by transduction of respiratory tract cells by an adenoviral vector, confers only partial protection, despite high levels of serum neutralizing activity. However, eliciting an immune response in the respiratory tract through an intranasal boost results in > 3 log10 decrease in the lung viral loads and reduces local inflammation. Moreover, both integrative and non-integrative LV platforms display strong vaccine efficacy and inhibit lung deleterious injury in golden hamsters, which are naturally permissive to SARS-CoV-2 replication and closely mirror human COVID-19 physiopathology. Our results provide evidence of marked prophylactic effects of the LV-based vaccination against SARS-CoV-2 and designate intranasal immunization as a powerful approach against COVID-19.